Listar por autor "Esteban, R."
Mostrando ítems 1-2 de 2
-
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort
Alonso, S.; Riveiro-Barciela, M.; Fernández, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernández-Carrillo, C.; Polo, B.; Carrión, J.A.; Gómez, A.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Ampuero, J.; Granados, R.; Pascasio, J.M.; Rubín, A.; Salmerón, J.; Badia, E.; Planas, J.M.M.; Lens, S.; Turnes, J.; Montero, J.L.; Buti, M.; Esteban, R.; Fernández-Rodríguez, C.M. (Wiley, 2016-11-09)[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or ... -
Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort
Riveiro-Barciela, M.; Alonso, Sonia; Fernández, Inmaculada; Rincón, Diego; Real, Yolanda; Crespo, Javier; Gea, Francisco; Olveira, Antonio; Calleja, J.L.; Polo-Lorduy, B.; Carrión, J.A.; Arenas, J.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Romero-Gómez, Manuel; Granados, R.; Pascasio, J.M.; Forns, Xavier; Turnes, Juan; Montero, J.L.; Esteban, R.; Fernández-Rodríguez, Conrado M. (Wiley, 2016-10)